Acme United's $6 Million Refund Masks a Made-in-America Retreat

The tariff windfall lifted Q3 EPS by 20 points; underneath, Acme closed its DMT plant and doubled down on a Tennessee factory.

ACU · Earnings Call · 2026-10-27

A beat with a refund inside it

Acme United reported a headline quarter that looks almost too good for a small-cap household-products company: net sales of $58 million, up 18%, net income of $3.4 million, up 80%, and diluted EPS of $0.80 versus $0.46. But the first thing management volunteered was the accounting bridge. “We received a tariff refund of $6 million, of which $4 million was brought into income, offset by reserves for closure of our small DMT facility and variable compensation.” — Walter Johnsen, Chairman and CEO · 2026-10-27 That refund contributed about $1 million after tax, or roughly $0.25 of EPS. Strip it out, and net income was $2.4 million, up 24%, while EPS was $0.55, up 20%. That is a good quarter — just not an 80% good quarter.

The gross margin tells the same story. Acme reported 45.3%, up from 39.1%, but Paul Driscoll disclosed that the quarter included roughly 690 basis points of benefit from the tariff refund, partly offset by 310 basis points tied to the DMT closure. The last filed quarter, before the refund, showed a 42.6% gross margin — respectable, but nowhere near the optical Q3 print. SG&A also jumped to 37.6% of sales from 32%, driven by the direct-to-consumer advertising required by MyMedic. The refund also triggered $1 million of variable compensation, a detail worth noting: even the windfall was shared internally before it reached shareholders.

Acme is not alone in this. The global keyword set shows tariff refunds surfacing across recent reporters — DECK, FSKRS, VAIAS, LIGHT — and the market-wide theme Tariff refund ranked first in Know Trend's 2026Q2 global keywords. ACU is riding a broad refund wave, but its own refund is a one-time cash event, not a recurring margin lever.

The plant Acme used to brag about

The more consequential disclosure was the decision to close the DMT sharpening plant in Marlborough, Massachusetts, reserve $1 million, and shift the remaining production to China. This is a reversal worth sitting with. In April 2025, Paul Driscoll described the business this way: “the DMT sharpening stones made in Marlborough, Massachusetts. They're arguably the best in the world.” — Paul Driscoll, Chief Financial Officer · 2025-04-17 Seventeen months later, Walter Johnsen explained why the same plant is being shuttered:“when the price of a product is just more expensive by a lot than in China to produce, sometimes the economics just drive you to do that.” — Walter Johnsen, Chairman and CEO · 2026-10-27 He stressed that the facility was small — fewer than 20 people — and that most DMT production had already been outsourced to China because customers wanted electronic sharpeners at competitive prices.

That is a company-unique strategic pivot, not a sector bromide. The keyword DMT closure is new to Acme's keyword set this quarter, and it sits awkwardly beside the broader reshoring rhetoric in the market. But Acme is not abandoning U.S. manufacturing wholesale. It is reallocating toward scale. The plant in Mount Pleasant, Tennessee — a 12-acre, 78,000-square-foot facility bought for $6 million with about $1.5 million of automation — is now fully operational for Spill Magic. Johnsen said the Spill Magic line is up roughly 34% year to date because the company finally has capacity. In July, he was even more animated about that business: “it is just-- it is really screaming.” — Walter C. Johnsen, Chairman and CEO · 2026-07-23 The contrast is the story: close the subscale plant where the brand began, pour capital into the plant with room to double. It is a classic capital-allocation decision dressed up as a tariff narrative.

MyMedic, inventory, and the balance sheet

MyMedic contributed $4 million of sales in the quarter and “performed as planned,” according to Johnsen. The acquisition is strategically interesting because it gives Acme a direct-to-consumer platform with higher gross margins but a much heavier advertising load. The MyMedic business is now the main reason SG&A is rising faster than sales. That is not necessarily bad — DTC can be a growth engine — but it changes the quality of Acme's earnings mix. In February, management sized MyMedic at roughly $19 million of annual sales and $1 million to $1.5 million of EBITDA, so a $4 million quarter is in the expected range.

The balance sheet is where the quarter gets less comfortable. Net debt rose to $29.7 million from $23.1 million a year earlier, after Acme paid $14.5 million for MyMedic, $2.4 million in dividends, and $1.6 million for a German cutting-and-sharpening line. The last filed balance sheet showed effective net cash of -$18 million, a swing from the net-cash position it held as recently as late 2023. Then there is the inventory bet.

We consciously increased our inventory by about $8 million-$10 million. ... The freight costs from China have tripled.
Walter Johnsen, Chairman and CEO · 2026-10-27

Johnsen said Acme is paying roughly 6% marginal interest on the debt used to carry that stock, and he expects to convert it back to cash in 2027. That could be smart — it protected Acme from shortages and price increases — but it is also a working-capital call that depends on a calmer 2027.

What the tape already knows

Acme's stock is up 45.8% over the last 90 trading days, a clean breakout in a name with a $252 million market cap. The tape has already voted that the tariff-refund quarter and the DMT cleanup are good news. The risk is that investors annualize the $1 million after-tax refund or the $1 million of expected annual DMT savings before either shows up cleanly in 2027 numbers. The underlying business grew EPS 20% — solid, but not the kind of number that usually justifies a 46% three-month move on its own.

Operationally, there are real positives. The Westcott business is recovering because last year's promotional calendar was frozen by tariff uncertainty; this year's back-to-school season had easy comparisons and better sell-through. First Aid remains about 70% of the company, and Johnsen reiterated that it is the natural consolidator in that space: “the First Aid business has greater organic growth opportunities ... it's 70% of our business.” — Walter Johnsen, Chairman and CEO · 2026-10-27 The automated production and filling equipment at Spill Magic also echo a broader industrial automation theme that has been visible in the global keyword set. But the consumer is still stressed, and management flagged heating oil, gasoline, mortgages, and interest rates as pressures on disposable income.

The quarter is best understood as a one-time refund funding a strategic cleanup. If Acme converts inventory to cash, keeps MyMedic growing, and delivers the DMT savings in 2027, the story holds together. If the market treats the refund as recurring, the next quarter will be a reminder that tariff windfalls are not a business model.